marketcaparena
Search

    IONS

    IONIS PHARMACEUTICALS INC

    Company overview

    Market capitalization
    $7.57B
    Employees
    1,402
    Latest publication
    2026-09-29
    About IONIS PHARMACEUTICALS INC

    Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ3 20242024-09-30 · USDQ1 20242024-03-31 · USDQ4 20232023-12-31 · USD
    Total Revenue267,949,000USD246,091,000USD156,719,000USD452,049,000USD131,612,000USD133,814,000USD119,497,000USD119,497,000USD
    Cost Of Revenue2,739,000USD2,983,000USD2,338,000USD4,151,000USD1,500,000USD1,071,000USD2,151,000USD2,151,000USD
    Gross Profit265,210,000USD243,108,000USD154,381,000USD447,898,000USD130,112,000USD132,743,000USD117,346,000USD117,346,000USD
    Selling General Administrative150,396,000USD150,400,000USD96,800,000USD90,600,000USD76,300,000USD61,600,000USD52,644,000USD52,644,000USD
    Total Operating Expenses367,503,000USD360,532,000USD314,563,000USD308,082,000USD276,972,000USD281,399,000USD266,859,000USD266,859,000USD
    Operating Income-102,293,000USD-117,424,000USD-160,182,000USD139,816,000USD-146,860,000USD-148,656,000USD-149,513,000USD-149,513,000USD
    Total Other Income Expense Net-11,089,000USD25,114,000USD31,789,000USD-16,285,000USD38,000USD4,555,000USD6,785,000USD6,785,000USD
    Interest Expense4,618,000USD22,497,000USD22,164,000USD22,762,000USD22,930,000USD22,694,000USD22,110,000USD22,110,000USD
    Income Before Tax-113,382,000USD-92,310,000USD-128,393,000USD123,531,000USD-146,822,000USD-144,101,000USD-142,728,000USD-142,728,000USD
    Income Tax Expense1,264,000USD218,000USD213,000USD-20,000USD116,000USD-3,621,000USD75,000USD75,000USD
    Net Income-114,646,000USD-92,528,000USD-128,606,000USD123,551,000USD-146,938,000USD-140,480,000USD-142,803,000USD-142,803,000USD
    Research Development—210,173,000USD217,754,000USD217,460,000USD200,759,000USD219,761,000USD214,215,000USD214,215,000USD
    Net Interest Income—-22,537,000USD-22,152,000USD-22,748,000USD-22,922,000USD-22,733,000USD-22,110,000USD-22,449,000USD
    Tax Provision—218,000USD213,000USD-20,000USD116,000USD-3,621,000USD75,000USD6,496,000USD
    Net Income From Continuing Ops—-92,528,000USD-128,606,000USD123,551,000USD-146,938,000USD-140,480,000USD-142,803,000USD-9,263,000USD
    Ebit—-75,310,000USD-107,841,000USD144,779,000USD-125,400,000USD-122,868,000USD-122,169,000USD-122,169,000USD
    Ebitda—-68,524,000USD-103,339,000USD150,233,000USD-120,003,000USD-117,375,000USD-116,518,000USD-116,518,000USD
    Depreciation And Amortization—6,786,000USD4,502,000USD5,454,000USD5,397,000USD5,493,000USD5,651,000USD5,651,000USD
    Reconciled Depreciation—7,447,000USD4,502,000USD5,454,000USD5,397,000USD5,493,000USD5,651,000USD5,612,000USD
    Selling And Marketing Expenses—————38,000USD—384,000USD
    Interest Income——————49,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20162016-12-31 · USDFY 20132013-12-31 · USDFY 20112011-12-31 · USDFY 20102010-12-31 · USDFY 19981998-12-31 · USD
    Total Revenue705,138,000USD787,647,000USD346,620,000USD147,285,000USD99,086,000USD108,473,000USD39,200,000USD
    Cost Of Revenue11,215,000USD9,133,000USD344,320,000USD184,033,000USD14,516,000USD35,423,000USD-4,300,000USD
    Gross Profit693,923,000USD778,514,000USD2,300,000USD-36,748,000USD99,086,000USD108,473,000USD43,500,000USD
    Research Development901,530,000USD899,625,000USD344,320,000USD184,033,000USD157,397,000USD145,160,000USD62,200,000USD
    Selling General Administrative267,500,000USD232,600,000USD48,616,000USD14,918,000USD12,789,000USD11,669,000USD—
    Selling And Marketing Expenses26,000USD——————
    Total Operating Expenses1,169,004,000USD1,132,244,000USD392,936,000USD198,951,000USD170,186,000USD156,829,000USD76,000,000USD
    Operating Income-475,081,000USD-353,730,000USD-46,316,000USD-51,666,000USD-71,100,000USD-48,356,000USD-32,500,000USD
    Interest Expense90,451,000USD81,457,000USD38,795,000USD19,355,000USD16,732,000USD13,232,000USD0USD
    Net Interest Income-90,457,000USD-81,497,000USD-38,795,000USD————
    Income Before Tax-460,068,000USD-333,965,000USD-83,622,000USD-66,558,000USD-84,790,000USD-61,159,000USD-33,500,000USD
    Income Tax Expense-6,171,000USD32,321,000USD2,934,000USD-5,914,000USD11,000USD92,000USD10,500,000USD
    Tax Provision-6,171,000USD32,321,000USD2,934,000USD————
    Net Income-453,897,000USD-366,286,000USD-86,556,000USD-60,644,000USD-84,801,000USD-61,251,000USD-43,000,000USD
    Net Income From Continuing Ops-453,897,000USD-366,286,000USD-86,556,000USD-60,644,000USD-84,801,000USD-61,251,000USD—
    Ebit-375,711,000USD-258,368,000USD-46,316,000USD-51,666,000USD-68,058,000USD-47,927,000USD-32,500,000USD
    Ebitda-353,721,000USD-235,870,000USD-37,283,000USD-41,884,000USD-56,274,000USD-38,750,000USD-28,200,000USD
    Depreciation And Amortization21,990,000USD22,498,000USD9,033,000USD9,782,000USD11,784,000USD9,177,000USD4,300,000USD
    Reconciled Depreciation21,990,000USD22,498,000USD—————
    Total Other Income Expense Net15,013,000USD19,765,000USD1,489,000USD4,463,000USD-13,690,000USD-12,803,000USD32,500,000USD
    Interest Income——33,323,000USD————
    Non Operating Income Net Other——1,433,000USD4,463,000USD3,042,000USD429,000USD—
    Minority Interest——84,267,000USD————
    Net Income Applicable To Common Shares——-86,556,000USD-60,644,000USD-84,801,000USD-61,251,000USD—
    Unclassified Operating Expenses——————13,800,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets2,994,501,000USD3,449,969,000USD3,523,836,000USD3,033,091,000USD2,985,133,000USD2,812,948,000USD3,003,675,000USD3,081,099,000USD
    Cash And Equivalents350,065,000USD———————
    Cash And Short Term Investments2,054,585,000USD1,919,113,000USD2,677,000,000USD2,240,000,000USD2,289,980,000USD2,145,152,000USD2,297,656,000USD2,483,276,000USD
    Short Term Investments1,704,520,000USD1,745,732,000USD2,305,176,000USD1,901,830,000USD1,992,676,000USD1,880,960,000USD2,055,579,000USD2,148,671,000USD
    Total Current Assets2,491,274,000USD2,936,945,000USD2,990,000,000USD2,518,993,000USD2,577,150,000USD2,418,932,000USD2,620,290,000USD2,713,850,000USD
    Other Current Assets327,011,000USD938,591,000USD247,000,000USD243,523,000USD226,109,000USD222,571,000USD217,934,000USD184,194,000USD
    Other Non Current Assets116,536,000USD———————
    Total Liabilities2,554,764,000USD———————
    Total Current Liabilities315,638,000USD716,591,000USD781,567,000USD903,456,000USD897,236,000USD250,293,000USD309,318,000USD304,566,000USD
    Other Current Liabilities25,149,000USD———————
    Other Non Current Liabilities28,435,000USD———————
    Total Stockholder Equity439,737,000USD491,414,000USD489,089,000USD617,967,000USD631,724,000USD475,726,000USD588,351,000USD662,468,000USD
    Total Equity Including Noncontrolling Interest439,737,000USD———————
    Deferred Revenue73,837,000USD———————
    Deferred Revenue Non Current63,030,000USD———————
    Inventory50,833,000USD5,557,000USD10,048,000USD10,470,000USD8,481,000USD11,502,000USD12,512,000USD28,452,000USD
    Property Plant Equipment Net386,691,000USD377,465,000USD362,000,000USD348,110,000USD275,884,000USD262,194,000USD256,107,000USD246,926,000USD
    Accounts Payable47,704,000USD26,030,000USD28,082,000USD14,326,000USD22,800,000USD17,456,000USD42,964,000USD9,052,000USD
    Common Stock166,000USD166,000USD163,000USD161,000USD159,000USD159,000USD158,000USD158,000USD
    Retained Earnings-2,838,369,000USD-2,723,723,000USD-2,631,195,000USD-2,401,801,000USD-2,273,195,000USD-2,396,746,000USD-2,249,808,000USD-2,145,459,000USD
    Accumulated Other Comprehensive Income-33,897,000USD-31,023,000USD-25,281,000USD-25,978,000USD-27,987,000USD-28,949,000USD-30,811,000USD-24,173,000USD
    Total Liab—2,958,555,000USD3,034,747,000USD2,415,124,000USD2,353,409,000USD2,337,222,000USD2,415,324,000USD2,418,631,000USD
    Other Current Liab—185,988,000USD226,578,000USD181,233,000USD168,327,000USD139,612,000USD178,052,000USD174,988,000USD
    Capital Stock—166,000USD163,000USD161,000USD159,000USD159,000USD158,000USD158,000USD
    Cash—173,381,000USD372,260,000USD338,341,000USD297,304,000USD264,192,000USD242,077,000USD334,605,000USD
    Current Deferred Revenue—69,199,000USD73,761,000USD76,986,000USD75,910,000USD81,097,000USD78,989,000USD76,018,000USD
    Net Debt—1,867,573,000USD2,242,065,000USD1,151,150,000USD1,122,687,000USD1,694,061,000USD1,174,492,000USD1,112,049,000USD
    Short Term Debt—432,500,000USD453,146,000USD630,911,000USD630,118,000USD12,002,000USD9,279,000USD44,467,000USD
    Short Long Term Debt—432,500,000USD454,686,000USD630,911,000USD630,118,000USD0USD9,279,000USD44,467,000USD
    Short Long Term Debt Total—2,040,954,000USD2,614,325,000USD1,489,491,000USD1,419,991,000USD1,958,253,000USD1,416,569,000USD1,446,654,000USD
    Long Term Debt—1,349,239,000USD1,347,443,000USD595,908,000USD625,494,000USD1,250,718,000USD1,245,485,000USD1,233,815,000USD
    Net Receivables—73,684,000USD66,000,000USD25,000,000USD52,580,000USD39,707,000USD92,188,000USD17,928,000USD
    Property Plant Equipment Gross—377,465,000USD470,677,000USD348,110,000USD275,884,000USD262,194,000USD362,423,000USD246,926,000USD
    Common Stock Shares Outstanding—164,874,000shares162,000,000shares160,758,000shares182,331,000shares158,735,000shares158,000,000shares148,593,000shares
    Non Current Assets Total—513,024,000USD533,200,999USD514,098,000USD407,983,000USD394,016,000USD383,385,000USD367,249,000USD
    Non Current Liabilities Total—2,241,964,000USD2,253,180,000USD1,511,668,000USD1,456,173,000USD2,086,929,000USD2,106,006,000USD2,114,065,000USD
    Non Current Liabilities Other—557,765,000USD551,353,000USD545,182,000USD541,205,000USD536,141,000USD542,212,000USD538,102,000USD
    Non Currrent Assets Other—135,559,000USD119,394,999USD113,778,000USD109,283,000USD90,799,000USD86,255,000USD79,300,000USD
    Net Working Capital—2,220,354,000USD2,209,068,000USD1,615,537,000USD1,679,914,000USD2,168,639,000USD2,310,972,000USD2,409,284,000USD
    Unclassified Current Liabilities—-429,626,000USD-454,686,000USD-630,911,000USD-630,037,000USD—-9,245,000USD-44,426,000USD
    Unclassified Non Current Liabilities—334,960,000USD354,384,000USD370,578,000USD289,474,000USD300,070,000USD318,309,000USD342,148,000USD
    Unclassified Equity—3,245,828,000USD3,145,239,000USD3,045,424,000USD2,932,588,000USD2,901,103,000USD2,868,654,000USD2,831,784,000USD
    Unclassified Non Current Assets——51,806,000USD52,210,000USD-396,184,000USD41,023,000USD41,023,000USD41,023,000USD
    Other Assets————419,000,000USD———
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets3,523,836,000USD3,003,675,000USD2,990,072,000USD2,533,876,000USD2,612,000,000USD2,390,000,000USD3,233,000,000USD2,667,784,000USD
    Other Current Assets247,000,000USD217,934,000USD205,433,000USD157,715,000USD168,000,000USD162,000,000USD158,000,000USD111,055,000USD
    Total Liab3,034,747,000USD2,415,324,000USD2,603,386,000USD1,960,989,000USD1,840,000,000USD1,547,000,000USD1,548,000,000USD1,480,624,000USD
    Total Stockholder Equity489,089,000USD588,351,000USD386,686,000USD572,887,000USD772,000,000USD843,000,000USD1,685,000,000USD1,187,160,000USD
    Other Current Liab226,578,000USD178,052,000USD215,621,000USD189,279,000USD127,570,000USD-128,360,000USD136,907,000USD77,629,000USD
    Common Stock163,000USD158,000USD144,000USD142,000USD141,000USD140,000USD140,000USD138,000USD
    Capital Stock163,000USD158,000USD144,000USD142,000USD141,000USD140,000USD140,000USD138,000USD
    Retained Earnings-2,631,195,000USD-2,249,808,000USD-1,795,911,000USD-1,429,625,000USD-1,159,903,000USD-1,249,368,000USD-707,534,000USD-967,293,000USD
    Cash372,260,000USD242,077,000USD399,266,000USD276,472,000USD2,115,000,000USD1,892,000,000USD2,500,000,000USD2,084,072,000USD
    Cash And Short Term Investments2,677,000,000USD2,297,656,000USD2,331,201,000USD1,997,408,000USD2,115,000,000USD1,892,000,000USD2,500,000,000USD2,084,072,000USD
    Total Current Assets2,990,000,000USD2,620,290,000USD2,641,853,000USD2,202,694,000USD2,345,000,000USD2,130,000,000USD2,721,000,000USD2,207,886,000USD
    Total Current Liabilities781,567,000USD309,318,000USD448,090,000USD311,561,000USD241,000,000USD290,000,000USD273,000,000USD280,294,000USD
    Current Deferred Revenue73,761,000USD78,989,000USD151,128,000USD90,577,000USD98,000,000USD108,000,000USD118,000,000USD160,256,000USD
    Net Debt2,242,065,000USD1,174,492,000USD1,054,273,000USD1,092,723,000USD-954,000,000USD-1,143,000,000USD-1,790,000,000USD-1,515,857,000USD
    Short Term Debt453,146,000USD9,279,000USD53,163,000USD7,535,000USD3,526,000USD293,161,000USD2,026,000USD13,749,000USD
    Short Long Term Debt454,686,000USD9,279,000USD53,163,000USD7,535,000USD3,526,000USD300,462,000USD2,026,000USD13,749,000USD
    Short Long Term Debt Total2,614,325,000USD1,416,569,000USD1,453,539,000USD1,369,195,000USD1,224,672,000USD808,864,000USD771,983,000USD641,806,000USD
    Long Term Debt1,347,443,000USD1,245,485,000USD1,229,501,000USD1,182,719,000USD1,221,146,000USD515,703,000USD769,957,000USD628,057,000USD
    Short Term Investments2,305,176,000USD2,055,579,000USD1,931,935,000USD1,720,936,000USD1,245,782,000USD1,494,711,000USD1,816,257,000USD1,805,252,000USD
    Net Receivables66,000,000USD92,188,000USD97,778,000USD25,538,000USD62,000,000USD76,000,000USD63,000,000USD12,759,000USD
    Inventory10,048,000USD12,512,000USD7,441,000USD22,033,000USD24,806,000USD21,965,000USD18,180,000USD8,582,000USD
    Accounts Payable28,082,000USD42,964,000USD26,027,000USD17,921,000USD11,904,000USD17,199,000USD16,067,000USD28,660,000USD
    Property Plant Equipment Net362,000,000USD256,107,000USD242,939,000USD255,838,000USD178,000,000USD181,000,000USD154,000,000USD132,160,000USD
    Property Plant Equipment Gross470,677,000USD362,423,000USD339,698,000USD256,000,000USD280,722,000USD181,077,000USD153,651,000USD132,160,000USD
    Accumulated Other Comprehensive Income-25,281,000USD-30,811,000USD-32,645,000USD-57,480,000USD-32,668,000USD-21,071,000USD-25,290,000USD-32,016,000USD
    Common Stock Shares Outstanding160,000,000shares149,514,000shares143,190,000shares141,848,000shares141,021,000shares139,612,000shares142,872,000shares134,056,000shares
    Non Current Assets Total533,200,999USD383,385,000USD348,219,000USD331,182,000USD267,000,000USD260,000,000USD512,000,000USD459,898,000USD
    Non Current Liabilities Total2,253,180,000USD2,106,006,000USD2,155,296,000USD1,649,428,000USD1,599,000,000USD1,257,000,000USD1,275,000,000USD1,200,330,000USD
    Non Current Liabilities Other551,353,000USD542,212,000USD513,736,000USD16,000,000USD378,257,000USD447,455,000USD505,603,000USD572,273,000USD
    Non Currrent Assets Other119,394,999USD86,255,000USD62,289,000USD34,972,000USD59,995,000USD51,063,000USD358,000,000USD327,738,000USD
    Net Working Capital2,209,068,000USD2,310,972,000USD2,193,763,000USD1,891,133,000USD2,104,000,000USD1,547,457,000USD2,447,592,000USD1,927,592,000USD
    Unclassified Non Current Assets51,806,000USD41,023,000USD42,991,000USD5,400,000USD-319,000,000USD-77,971,000USD-346,264,000USD-327,738,000USD
    Unclassified Current Liabilities-454,686,000USD-9,245,000USD-51,012,000USD—-3,526,000USD-428,822,000USD—-13,749,000USD
    Unclassified Non Current Liabilities354,384,000USD318,309,000USD412,059,000USD162,941,000USD-352,403,000USD-130,158,000USD-490,620,000USD-567,359,000USD
    Unclassified Equity3,145,239,000USD2,868,654,000USD2,214,954,000USD2,059,708,000USD1,964,289,000USD2,113,159,000USD2,417,544,000USD2,186,193,000USD
    Other Liab———287,768,000USD352,000,000USD424,000,000USD490,060,000USD567,359,000USD
    Other Assets———34,972,000USD319,000,000USD77,971,000USD310,590,000USD303,706,000USD
    Net Tangible Assets———572,887,000USD742,732,000USD815,410,000USD1,445,420,000USD1,024,047,000USD
    Intangible Assets————29,005,000USD27,937,000USD25,674,000USD24,032,000USD
    Unclassified Current Assets————-1,270,588,000USD-1,516,676,000USD-1,834,437,000USD-1,813,834,000USD
    Long Term Investments——————10,000,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation8,095,000USD
    Stock Based Compensation88,870,000USD
    Change To Inventory-24,626,000USD
    Change To Liabilities31,434,000USD
    Change In Working Capital-44,144,000USD
    Operating Cash Flow-227,288,000USD
    Capital Expenditures-37,843,000USD
    Net Investments601,800,000USD
    Unclassified Investing Cash Flow-3,640,000USD
    Investing Cash Flow560,317,000USD
    Common Stock Issuance77,560,000USD
    Unclassified Financing Cash Flow-432,596,000USD
    Financing Cash Flow-355,036,000USD
    Effect Of Forex Changes On Cash-188,000USD
    Change In Cash-22,195,000USD
    End Cash Flow350,065,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-92,528,000USD-229,000,000USD-128,606,000USD123,551,000USD-146,938,000USD-104,349,000USD-140,480,000USD-66,265,000USD
    Depreciation6,786,000USD7,341,000USD11,851,000USD5,454,000USD4,815,000,000USD5,267,000USD3,616,000USD5,579,000USD
    Stock Based Compensation43,275,000USD-29,644,962,000USD31,146,000USD29,690,000USD29,718,000USD36,148,000USD31,984,000USD30,728,000USD
    Other Non Cash Items-20,228,000USD60,094,000USD-115,486,000USD21,126,000USD-4,807,380,000USD8,180,000USD-149,656,000USD4,104,000USD
    Change To Account Receivables-7,625,000USD-41,451,000USD-39,608,000USD-12,873,000USD52,481,000USD-74,260,000USD9,331,000USD-22,119,000USD
    Change To Inventory338,000USD926,000USD12,465,000USD-13,475,000USD1,010,000USD-5,044,000USD271,000USD1,536,000USD
    Change In Working Capital-730,124,000USD23,856,000USD69,658,000USD-28,483,000USD-41,175,000USD-61,385,000USD139,546,000USD-94,026,000USD
    Total Cash From Operating Activities-792,819,000USD-137,709,000USD-131,437,000USD151,338,000USD-150,775,000USD-116,139,000USD-114,990,000USD-119,880,000USD
    Capital Expenditures-21,763,000USD-21,292,000USD-3,306,000USD-14,269,000USD-12,577,000USD-25,497,000USD-9,056,000USD-20,261,000USD
    Free Cash Flow-814,582,000USD-159,001,000USD-134,743,000USD137,069,000USD-163,352,000USD-141,636,000USD-124,046,000USD-140,141,000USD
    Investments560,069,000USD-396,848,000USD91,338,000USD-120,068,000USD170,459,000USD68,213,000USD-340,795,000USD62,450,000USD
    Total Cashflows From Investing Activities536,820,000USD-419,505,000USD91,338,000USD-120,068,000USD170,459,000USD68,213,000USD-340,795,000USD62,450,000USD
    Net Borrowings-44,000USD502,308,000USD-41,000USD-40,000USD-42,000USD-44,545,000USD-48,000USD—
    Total Cash From Financing Activities57,258,000USD591,176,000USD81,218,000USD1,247,000USD2,199,000USD-44,116,000USD496,047,000USD2,557,000USD
    Issuance Of Capital Stock57,302,000USD107,817,000USD81,259,000USD1,287,000USD2,241,000USD429,000USD496,095,000USD2,596,000USD
    Change In Cash-198,879,000USD33,919,000USD41,037,000USD33,112,000USD22,115,000USD-92,528,000USD40,612,000USD-54,896,000USD
    Begin Period Cash Flow372,260,000USD338,341,000USD297,304,000USD264,192,000USD242,077,000USD334,605,000USD293,993,000USD348,889,000USD
    End Period Cash Flow173,381,000USD372,260,000USD338,341,000USD297,304,000USD264,192,000USD242,077,000USD334,605,000USD293,993,000USD
    Other Cashflows From Investing Activities-1,486,000USD170,937,525,000USD-1,660,000USD-1,964,000USD-651,000USD-2,547,000USD12,750,000USD-14,027,000USD
    Other Cashflows From Financing Activities57,258,000USD-1,605,625,000USD106,765,000USD—-42,000USD—496,095,000USD62,450,000USD
    Unclassified Financing Cash Flow-57,258,000USD1,586,676,000USD-84,787,000USD———-496,095,000USD-62,489,000USD
    Unclassified Operating Cash Flow—29,644,962,000USD——————
    Unclassified Investing Cash Flow—-170,938,890,000USD4,966,000USD16,233,000USD13,228,000USD28,044,000USD-3,694,000USD34,288,000USD
    Dividends Paid——-21,978,000USD—————
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-381,387,000USD-453,897,000USD-366,286,000USD-269,722,000USD-28,597,000USD-486,766,000USD303,262,000USD214,985,000USD
    Depreciation22,694,000USD19,654,000USD22,498,000USD22,105,000USD19,560,000USD17,160,000USD15,994,000USD12,528,000USD
    Stock Based Compensation133,874,000USD130,200,000USD105,809,000USD100,264,000USD120,678,000USD230,117,000USD146,574,000USD131,312,000USD
    Other Non Cash Items7,451,000USD12,486,000USD7,726,000USD-134,588,000USD7,665,000USD35,664,000USD55,694,000USD35,172,000USD
    Change To Account Receivables26,129,000USD5,590,000USD-72,059,000USD36,358,000USD5,050,000USD-22,000,000USD-44,178,000USD514,000USD
    Change To Inventory-13,674,000USD-5,071,000USD-6,392,000USD2,773,000USD-2,841,000USD-1,261,000USD-5,411,000USD1,400,000USD
    Change In Working Capital-51,215,000USD-209,390,000USD-77,260,000USD7,571,000USD-113,818,000USD-73,555,000USD-168,708,000USD499,407,000USD
    Total Cash From Operating Activities-268,583,000USD-500,947,000USD-307,513,000USD-274,370,000USD30,799,000USD35,892,000USD345,720,000USD602,888,000USD
    Capital Expenditures-51,444,000USD-45,280,000USD-28,011,000USD-20,099,000USD-17,901,000USD-41,048,000USD-36,282,000USD-17,652,000USD
    Free Cash Flow-320,027,000USD-546,227,000USD-335,524,000USD-294,469,000USD12,898,000USD-5,156,000USD309,438,000USD585,236,000USD
    Investments-220,692,000USD-134,027,000USD24,733,000USD-262,636,000USD212,807,000USD315,525,000USD-4,992,000USD-911,911,000USD
    Total Cashflows From Investing Activities-277,776,000USD-134,027,000USD-214,127,000USD-262,636,000USD194,906,000USD274,477,000USD-41,274,000USD-929,563,000USD
    Net Borrowings502,185,000USD-44,671,000USD86,897,000USD-50,686,000USD418,304,000USD313,570,000USD-22,112,000USD97,000,000USD
    Total Cash From Financing Activities675,840,000USD478,058,000USD644,082,000USD-55,295,000USD245,933,000USD-596,609,000USD100,021,000USD475,865,000USD
    Issuance Of Capital Stock192,604,000USD522,729,000USD9,023,000USD6,373,000USD11,565,000USD52,036,000USD119,657,000USD475,865,000USD
    Change In Cash130,183,000USD-157,189,000USD122,794,000USD-592,719,000USD471,527,000USD-285,623,000USD404,467,000USD149,190,000USD
    Begin Period Cash Flow242,077,000USD399,266,000USD276,472,000USD869,191,000USD397,664,000USD683,287,000USD278,820,000USD129,630,000USD
    End Period Cash Flow372,260,000USD242,077,000USD399,266,000USD276,472,000USD869,191,000USD397,664,000USD683,287,000USD278,820,000USD
    Other Cashflows From Investing Activities-5,640,000USD-5,061,000USD-4,206,000USD254,083,000USD-5,946,000USD-5,928,000USD-5,377,000USD-4,044,000USD
    Other Cashflows From Financing Activities675,840,000USD522,729,000USD507,743,000USD-10,982,000USD-153,345,000USD-558,097,000USD203,294,000USD475,865,000USD
    Unclassified Financing Cash Flow-694,789,000USD-522,729,000USD40,419,000USD28,279,000USD14,424,000USD-261,534,000USD118,841,000USD-572,865,000USD
    Unclassified Investing Cash Flow—50,341,000USD-206,643,000USD-233,984,000USD5,946,000USD5,928,000USD5,377,000USD—
    Change To Liabilities———64,370,000USD-42,587,000USD-5,663,000USD23,402,000USD2,752,000USD
    Dividends Paid———-10,953,000USD-16,725,000USD—-165,610,000USD—
    Sale Purchase Of Stock———-10,953,000USD-16,725,000USD-90,548,000USD-34,392,000USD475,865,000USD
    Cash And Cash Equivalents Changes———-592,301,000USD471,527,000USD-285,623,000USD404,467,000USD149,190,000USD
    Exchange Rate Changes————-111,000USD617,000USD——
    Unclassified Operating Cash Flow————25,311,000USD313,272,000USD-7,096,000USD-290,516,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductCollaborative Agreement Revenue120,660,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductDAWNZERASales15,855,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductOther Commercial6,532,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductRoyalty — Other Royalties3,904,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductRoyalty — Spinraza Royalties43,710,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductRoyalty — Wainus Royalties10,709,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductTryngolza27,100,000USD0000874015-26-000177
    Q1 2026Quarterly · 2026-03-31ProductWainua Joint Development Revenue17,621,000USD0000874015-26-000177
    FY 2025Yearly · 2025-12-31ProductCollaborative Agreement Revenue465,785,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductDawnzera Sales7,789,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductOther Commercial35,004,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductRoyalty — Other Royalties24,159,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductRoyalty — Spinraza Royalties212,280,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductRoyalty — Wainus Royalties49,090,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductTryngolza Sales107,526,000USD0000874015-26-000115
    FY 2025Yearly · 2025-12-31ProductWainua Joint Development Revenue42,078,000USD0000874015-26-000115
    Q1 2025Quarterly · 2025-03-31ProductCollaborative Agreement Revenue45,031,000USD0000874015-26-000177
    Q1 2025Quarterly · 2025-03-31ProductDAWNZERASales0USD0000874015-26-000177
    Q1 2025Quarterly · 2025-03-31ProductOther Commercial12,002,000USD0000874015-26-000177
    Q1 2025Quarterly · 2025-03-31ProductRoyalty — Other Royalties6,784,000USD0000874015-26-000177
    Q1 2025Quarterly · 2025-03-31ProductRoyalty — Spinraza Royalties48,010,000USD0000874015-26-000177
    Q1 2025Quarterly · 2025-03-31ProductRoyalty — Wainus Royalties9,372,000USD0000874015-26-000177
    Q1 2025Quarterly · 2025-03-31ProductWainua Joint Development Revenue10,413,000USD0000874015-26-000177
    Q3 2024Quarterly · 2024-09-30ProductCollaborative Agreement Revenue44,883,000USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductOther Commercial8,924,000USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductProduct0USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductRoyalty — Other Royalties4,228,000USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductRoyalty — Spinraza Royalties57,208,000USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductRoyalty — Wainus Royalties5,371,000USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductTryngolza0USD0000874015-25-000266
    Q3 2024Quarterly · 2024-09-30ProductWainua Joint Development Revenue13,200,000USD0000874015-25-000266
    Q2 2024Quarterly · 2024-06-30ProductCollaborative Agreement Revenue141,524,000USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductOther0USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductProduct0USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductRoyalty — Other Royalties11,512,000USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductRoyalty — Spinraza Royalties56,743,000USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductRoyalty — Wainus Royalties3,781,000USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductTryngolza0USD0000874015-25-000167
    Q2 2024Quarterly · 2024-06-30ProductWainua Joint Development Revenue11,690,000USD0000874015-25-000167
    Q1 2024Quarterly · 2024-03-31ProductCollaborative Agreement Revenue49,345,000USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductOther1,580,000USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductOther Commercial — Tegsedi And Waylivra8,628,000USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductProduct0USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductRoyalty — Other Royalties9,805,000USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductRoyalty — Spinraza Royalties38,455,000USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductRoyalty — Wainus Royalties1,125,000USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductTryngolza0USD0000874015-25-000123
    Q1 2024Quarterly · 2024-03-31ProductWainua Joint Development Revenue10,559,000USD0000874015-25-000123
    Q4 2023Quarterly · 2023-12-31ProductCollaborative Agreement Revenue179,143,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductOther7,484,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductOther Commercial — Product9,494,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductSpinraza Royalties61,867,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductWainua Joint Development Revenue66,517,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31ProductWainus Royalties0USDLegacy provider
    FY 2023Yearly · 2023-12-31ProductCollaborative Agreement Revenue352,657,000USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductDawnzera Sales0USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductOther Commercial35,788,000USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductProduct0USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductRoyalty — Other Royalties32,424,000USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductRoyalty — Spinraza Royalties240,379,000USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductTryngolza Sales0USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductWainua Joint Development Revenue126,399,000USD0000874015-26-000115
    FY 2023Yearly · 2023-12-31ProductWainus Royalties0USD0000874015-26-000115
    Q3 2023Quarterly · 2023-09-30ProductCollaborative Agreement Revenue44,167,000USD0000874015-24-000232
    Q3 2023Quarterly · 2023-09-30ProductLicensing And Other Royalties8,542,000USD0000874015-24-000232
    Q3 2023Quarterly · 2023-09-30ProductOther Commercial — Product8,286,000USD0000874015-24-000232
    Q3 2023Quarterly · 2023-09-30ProductSpinraza Royalties67,253,000USD0000874015-24-000232
    Q3 2023Quarterly · 2023-09-30ProductWainua Joint Development Revenue15,959,000USD0000874015-24-000232
    Q3 2023Quarterly · 2023-09-30ProductWainus Royalties0USD0000874015-24-000232
    Q2 2023Quarterly · 2023-06-30ProductCollaborative Agreement Revenue91,013,000USD0000874015-24-000187
    Q2 2023Quarterly · 2023-06-30ProductLicensing And Other Royalties6,230,000USD0000874015-24-000187
    Q2 2023Quarterly · 2023-06-30ProductOther Commercial — Product10,655,000USD0000874015-24-000187
    Q2 2023Quarterly · 2023-06-30ProductSpinraza Royalties61,012,000USD0000874015-24-000187
    Q2 2023Quarterly · 2023-06-30ProductWainua Joint Development Revenue19,501,000USD0000874015-24-000187
    Q2 2023Quarterly · 2023-06-30ProductWainus Royalties0USD0000874015-24-000187
    FY 2022Yearly · 2022-12-31ProductCollaborative Agreement Revenue207,222,000USD0000874015-25-000089
    FY 2022Yearly · 2022-12-31ProductOther30,993,000USD0000874015-25-000089
    FY 2022Yearly · 2022-12-31ProductOther Commercial — Product30,051,000USD0000874015-25-000089
    FY 2022Yearly · 2022-12-31ProductSpinraza Royalties242,314,000USD0000874015-25-000089
    FY 2022Yearly · 2022-12-31ProductWainua Joint Development Revenue76,787,000USD0000874015-25-000089
    FY 2022Yearly · 2022-12-31ProductWainus Royalties0USD0000874015-25-000089
    Q3 2020Quarterly · 2020-09-30SegmentAkcea Therapeutics19,470,000USD0000874015-20-000142
    Q3 2020Quarterly · 2020-09-30SegmentIonis Core141,455,000USD0000874015-20-000142
    Q1 2020Quarterly · 2020-03-31SegmentAkcea Therapeutics16,074,000USD0001140361-20-010825
    Q1 2020Quarterly · 2020-03-31SegmentIonis Core118,097,000USD0001140361-20-010825
    FY 2019Yearly · 2019-12-31ProductCommercial — Licensing And Other Royalties17,205,000USD0000874015-22-000079
    FY 2019Yearly · 2019-12-31ProductCommercial — Product42,253,000USD0000874015-22-000079
    FY 2019Yearly · 2019-12-31ProductCommercial — Spinraza Royalties292,992,000USD0000874015-22-000079
    FY 2019Yearly · 2019-12-31ProductResearch And Development Revenue Under Collaborative Agreements770,149,000USD0000874015-22-000079
    FY 2018Yearly · 2018-12-31ProductCommercial — Licensing And Other Royalties14,755,000USD0000874015-21-000056
    FY 2018Yearly · 2018-12-31ProductCommercial — Product2,237,000USD0000874015-21-000056
    FY 2018Yearly · 2018-12-31ProductCommercial — Spinraza Royalties237,930,000USD0000874015-21-000056
    FY 2018Yearly · 2018-12-31ProductResearch And Development Revenue Under Collaborative Agreements344,752,000USD0000874015-21-000056
    Q2 2018Quarterly · 2018-06-30SegmentAkcea Therapeutics18,321,000USD0001140361-19-014492
    Q2 2018Quarterly · 2018-06-30SegmentIonis Core99,426,000USD0001140361-19-014492
    FY 2017Yearly · 2017-12-31ProductCommercial — Licensing And Other Royalties7,474,000USD0001140361-20-004500
    FY 2017Yearly · 2017-12-31ProductCommercial — SPINRAZARoyalties112,540,000USD0001140361-20-004500
    FY 2017Yearly · 2017-12-31ProductProduct0USD0001140361-20-004500
    FY 2017Yearly · 2017-12-31ProductResearch And Development Revenue Under Collaborative Agreements394,165,000USD0001140361-20-004500
    Q3 2017Quarterly · 2017-09-30SegmentAkcea Therapeutics9,906,000USD0000874015-18-000128

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.